SLC5A2 and chronic kidney disease: In fact, the latest guidelines from the ADA (2022) have now changed the recommendation to state that GLP-1 RAs and SGLT-2 inhibitors, with or without metformin, “are appropriate initial therapy for individuals with T2DM with or at high risk for atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease” [1].